Showing results (141-150 of 163) with videos related to
Sort By:
Pageof 17
The Journal of Experimental Medicine|August 3, 2005
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersMark Cobbold, Naeem Khan, Batoul Pourgheysari, et al.Blood|February 29, 2012
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantationAristeidis Chaidos, Scott Patterson, Richard Szydlo, et al.Blood|May 20, 2006
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMichele Baccarani, Giuseppe Saglio, John Goldman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.Blood|February 25, 2011
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyAmr R Ibrahim, Lina Eliasson, Jane F Apperley, et al.Blood|October 13, 2007
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatmentAndreas Hochhaus, Brian Druker, Charles Sawyers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibDavid Marin, Alexandra Bazeos, Francois-Xavier Mahon, et al.Leukemia|February 5, 2020
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trialStuart J Blakemore, Ruth Clifford, Helen Parker, et al.Blood Advances|August 23, 2019
Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trialsTomasz K Wojdacz, Harindra E Amarasinghe, Latha Kadalayil, et al.Pageof 17